The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings
Selecting biologics with near-term biosimilar competition for IRA negotiation may produce short-term savings but forgo greater long-term savings achievable through competition.
Authors
- Priyanka Ghule (ORCID: https://orcid.org/0000-0003-0437-2066)
- S.W. Ko
- William B. Wong (ORCID: https://orcid.org/0000-0002-6054-278X)
- James D. Chambers (ORCID: https://orcid.org/0000-0001-5696-4894)
- Fariel LaMountain (ORCID: https://orcid.org/0009-0002-1934-7058)
- Molly T. Beinfeld
Institutions
- Tufts Medical Center (US)
- Unity Health System (US)
Publication Details
- Journal
- Health Affairs Scholar
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/haschl/qxaf222
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genentech